[ET Net News Agency, 23 September 2021] CSPC Pharmaceutical Group Limited (01093) said
on 22 September 2021, Shanghai JMT-Bio Technology Co., Ltd. (JMT-Bio), a wholly-owned
subsidiary of the company, has entered into a strategic alliance agreement with Keymed
Bioscience (Chengdu) Co., Ltd. (Chengdu Keymed), a wholly-owned subsidiary of Keymed
Biosciences Inc. (Keymed Bio).
Under the terms of the agreement, JMT-Bio and Chengdu Keymed shall jointly identify,
research, develop and commercialize one or more products for nervous system diseases (the
collaboration products). JMT-Bio will primarily be responsible for clinical development
and commercialization of the collaboration products and Chengdu Keymed will primarily be
responsible for pre-clinical research and development of the collaboration products. (RC)